An ulcerative colitis taxonomy defined by individual patient-reported response trajectories

What To Know

Researchers analyzed patient-reported outcomes from two phase 3 trials and several real-world cohorts to define four distinct response-trajectory groups for vedolizumab and adalimumab in ulcerative colitis.

The study links specific vedolizumab response trajectories to long-term disease complications and explores molecular features (including single-cell and spatial transcriptomics/proteomics) associated with nonresponse.

The team identified vascular inflammation, involving interactions between SPP1+ macrophages and endothelial cells, as a signature tied to vedolizumab nonresponse. In large real-world cohorts, concurrent use of renin–angiotensin system inhibitors was associated with fewer long-term complications in patients on vedolizumab but not with anticytokine therapy.

This work proposes a response-trajectory-based taxonomy that could help stratify patients and suggest combination strategies for vedolizumab, but the authors state it requires prospective validation before clinical use. Keep the focus on the study design and exploratory molecular findings; this is not a treatment recommendation.